Melatonin for Insomnia in Children With Autism Spectrum Disorders

Abstract

We describe our experience in using melatonin to treat insomnia, a common sleep concern, in children with autism spectrum disorders. One hundred seven children (2—18 years of age) with a confirmed diagnosis of autism spectrum disorders who received melatonin were identified by reviewing the electronic medical records of a single pediatrician. All parents were counseled on sleep hygiene techniques. Clinical response to melatonin, based on parental report, was categorized as (1) sleep no longer a concern, (2) improved sleep but continued parental concerns, (3) sleep continues to be a major concern, and (4) worsened sleep. The melatonin dose varied from 0.75 to 6 mg. After initiation of melatonin, parents of 27 children (25%) no longer reported sleep concerns at follow-up visits. Parents of 64 children (60%) reported improved sleep, although continued to have concerns regarding sleep. Parents of 14 children (13%) continued to report sleep problems as a major concern, with only 1 child having worse sleep after starting melatonin (1%), and 1 child having undetermined response (1%). Only 3 children had mild side-effects after starting melatonin, which included morning sleepiness and increased enuresis. There was no reported increase in seizures after starting melatonin in children with pre-existing epilepsy and no new-onset seizures. The majority of children were taking psychotropic medications. Melatonin appears to be a safe and well-tolerated treatment for insomnia in children with autism spectrum disorders. Controlled trials to determine efficacy appear warranted.

Keywords

sleep pervasive developmental disorder—not otherwise specified Asperger syndrome melatonin

Get full access to this article

View all access options for this article.

References

Richdale AL Sleep problems in autism: prevalence, cause, and intervention. Dev Med Child Neurol. 1999;41:60-66.

Williams G. , Sears LL , Allard AM Sleep problems in children with autism. J Sleep Res. 2004;13:265-268.

Zhdanova, IV , Wurtman RJ , Wagstaff J. Effects of a low dose of melatonin on sleep in children with Angelman syndrome. J Pediatr Endocrinol Metab . 1999;12:57-67.

Wheeler B. , Taylor B. , Simonsen K. , Reith D.

Melatonin treatment in Smith-Magenis syndrome

Sleep. 2005;28:1609-1610.

Miyamoto A. , Junichi O. , Takahashi S. , Okuno A. Serum melatonin kinetics and long-term melatonin treatment for sleep disorders in Rett syndrome. Brain Dev. 1999;21:59-62.

Sheldon SH Pro-convulsant effects of oral melatonin in neurologically disabled children . Lancet. 1998;27:351:1963-1964.

Jan JE , Hamilton D. , Seward N. , et al. Clinical trials of controlled-release melatonin in children with sleep-wake cycle disorders. J Pineal Res. 2000;29:34-39.

Tordjman S. , Anderson GM , Pichard N. , et al. Nocturnal excretion of 6-sulphatoxymelatonin in children and adolescents with autistic disorder. J Biol Psychiatry. 2005;57:134-138.

Jan JE , Esperzedl H. , Appleton RE The treatment of sleep disorders with melatonin. Dev Med Child Neurol. 1994;36:97-107.

10.

Paavonen EJ , Nieminen-von Wendt T. , Vanhala R. , et al. Effectiveness of melatonin in the treatment of sleep disturbances in children with Asperger disorder. J Child Adolesc Psychopharmacol. 2003;13:83-95.

11.

Giannotti F. , Cortesi F. , Cerquiglini A. , Bernabei P. An open-label study of controlled-release melatonin in treatment of sleep disorders in children with autism. J Autism Dev Disord. 2006;36: 741-752.

12.

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Text Revision. Washington, DC: American Psychiatric Association; 2000.

13.

Malow BA , Marzec ML , McGrew SG , et al. Characterizing sleep in children with autism spectrum disorders: a multidimensional approach. Sleep. 2006;29:1563-1571.